Preclinical characterization of a Selective FGFR2/3 inhibitor, GSC000829

被引：0
|
作者：
Han, T. [1 ]
Fu, D. [1 ]
Cheng, T. [1 ]
Xia, Y. [1 ]
Hu, Z. [1 ]
Yang, F. [1 ]
机构：
[1] Changchun GeneSci Pharmaceut Co Ltd, Chem Drug Res & Dev, Shanghai, Peoples R China
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114647
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB112
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [1] Preclinical characterization of alofanib, a novel allosteric FGFR2 inhibitor
    Tsimafeyeu, I.
    Stepanova, E.
    Khochenkov, D.
    Murillo, G.
    Lapina, N.
    Gavrilova, E.
    Byakhov, M.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Toxicity of selective allosteric FGFR2 inhibition in preclinical studies
    Lapina, Nataliya V.
    Melikhova, Marina V.
    Vakunenkova, Olga A.
    Kashuro, Vadim A.
    CANCER RESEARCH, 2016, 76
  • [3] Preclinical characterization of the selective FGFR inhibitor INCB054828
    Liu, Phillip C. C.
    Wu, Liangxing
    Koblish, Holly
    Bowman, Kevin
    Zhang, Yue
    Klabe, Ronald
    Leffet, Lynn
    DiMatteo, Darlise
    Rupar, Mark
    Gallagher, Karen
    Hansbury, Michael
    Zhang, Colin
    He, Chunhong
    Collier, Paul
    Covington, Maryanne
    Wynn, Richard
    Yeleswaram, Swamy
    Vaddi, Kris
    Burn, Timothy
    Yao, Wenqing
    Huber, Reid
    Scherle, Peggy
    Hollis, Gregory
    CANCER RESEARCH, 2015, 75
  • [4] Discovery of a highly potent and selective FGFR2 inhibitor for FGFR2-driven cancers
    Li, Wenqian
    Liu, Bin
    Wang, Junmei
    Yin, Tinggui
    Yu, Kuo-Long
    Kumar, Sanjeev
    Wen, Zhiming
    Zhao, Genshi
    Pan, Weitao
    CANCER RESEARCH, 2024, 84 (06)
  • [5] In vivo characterization of a selective FGFR2 inhibitor with potency against gatekeeper and molecular brake mutations
    Fischer, John
    Bouhana, Karyn
    Chicarelli, Mark
    Fell, Brad
    Fulton, Jennifer
    Guarnieri, Anna
    Haygood, Leyla
    Jalluri, Ravi
    Johnson, Amber
    Mclean, Brent
    Mejia, Max
    Rieger, Rob
    Robinson, John
    Rodriguez, Mareli
    Sullivan, Francis
    Wang, Yang
    Winski, Shannon
    Zhou, YeYun
    CANCER RESEARCH, 2023, 83 (07)
  • [6] Characterization of two novel oncogenic FGFR2 fusions sensitive to the FGFR-selective inhibitor Debio 1347 in cholangiocarcinoma
    Vaslin, Anne
    Rigotti, Stefania
    Lembrez, Nathalie
    Vuagniaux, Gregoire
    Moulon, Corinne
    Tanaka, Hiroaki
    CANCER RESEARCH, 2015, 75
  • [7] RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
    Subbiah, Vivek
    Sahai, Vaibhav
    Maglic, Dejan
    Bruderek, Kamil
    Toure, B. Barry
    Zhao, Songping
    Valverde, Roberto
    O'Hearn, Patrick J.
    Moustakas, Demetri T.
    Schoenherr, Heike
    Gerami-Moayed, Nastaran
    Taylor, Alexander M.
    Hudson, Brandi M.
    Houde, Damian J.
    Pal, Debjani
    Foster, Lindsey
    Gunaydin, Hakan
    Ayaz, Pelin
    Sharon, Dina A.
    Goyal, Lipika
    Schram, Alison M.
    Kamath, Suneel
    Sherwin, Cori Ann
    Schmidt-Kittler, Oleg
    Jen, Kai Yu
    Ricard, Fabien
    Wolf, Beni B.
    Shaw, David E.
    Bergstrom, Donald A.
    Watters, James
    Casaletto, Jessica B.
    CANCER DISCOVERY, 2023, 13 (09) : 2012 - 2031
  • [8] Discovery and preclinical characterization of ISM8001, a covalent and selective FGFR2/FGFR3 dual inhibitor with strong monotherapy anti-tumor activity against advanced solid tumors
    Zhang, Yihong
    Wang, Yazhou
    Cai, Xin
    Liu, Jinxin
    Cui, Hui
    Qiao, Junwen
    Lin, Xiaoxia
    Ding, Xiao
    Bavadekar, Supriya
    Rao, Sujata
    Zhang, Man
    Ren, Feng
    Zhavoronkov, Alex
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models
    Guffanti, F.
    Chila, R.
    Bello, E.
    Ceriani, L.
    Zangarini, M.
    Zucchetti, M.
    Saba, C.
    Jacquet-Bescond, A.
    Pierrat, M.
    Damia, G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 110 - 110
  • [10] Design and preclinical profile of CH5183284/Debio 1347, a novel orally available and selective FGFR inhibitor acting on a gatekeeper mutant of FGFR2
    Ebiike, Hirosato
    Taka, Naoki
    Nakanishi, Yoshito
    Akiyama, Nukinori
    Sawamura, Fumie
    Morikami, Kenji
    Matsushita, Masayuki
    Ohmori, Masayuki
    Takami, Kyouko
    Hyohdoh, Ikumi
    Kohchi, Masami
    Hayase, Tadakatsu
    Nishii, Hiroki
    Ishii, Nobuya
    Matsuoka, Hiroharu
    CANCER RESEARCH, 2014, 74 (19)
12345